Donald F Slack1, Douglas S Corwin, Nirav G Shah, Carl B Shanholtz, Avelino C Verceles, Giora Netzer, Kevin M Jones, Clayton H Brown, Michael L Terrin, Jeffrey D Hasday. 1. 1Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD.2Program in Trauma, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD.3Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, MD.4Medicine and Research Services, Baltimore Veterans Affairs Medical Care System, Baltimore, MD.
Abstract
OBJECTIVES: Prior studies suggest hypothermia may be beneficial in acute respiratory distress syndrome, but cooling causes shivering and increases metabolism. The objective of this study was to assess the feasibility of performing a randomized clinical trial of hypothermia in patients with acute respiratory distress syndrome receiving treatment with neuromuscular blockade because they cannot shiver. DESIGN: Retrospective study and pilot, prospective, open-label, feasibility study. SETTING: Medical ICU. PATIENTS: Retrospective review of 58 patients with acute respiratory distress syndrome based on Berlin criteria and PaO2/FIO2 less than 150 who received neuromuscular blockade. Prospective hypothermia treatment in eight acute respiratory distress syndrome patients with PaO2/FIO2 less than 150 receiving neuromuscular blockade. INTERVENTION: Cooling to 34-36°C for 48 hours. MEASUREMENTS AND MAIN RESULTS: Core temperature, hemodynamics, serum glucose and electrolytes, and P/F were sequentially measured, and medians (interquartile ranges) presented, 28-day ventilator-free days, and hospital mortality were calculated in historical controls and eight cooled patients. Average patient core temperature was 36.7°C (36-37.3°C), and fever occurred during neuromuscular blockade in 30 of 58 retrospective patients. In the prospectively cooled patients, core temperature reached target range less than or equal to 4 hours of initiating cooling, remained less than 36°C for 92% of the 48 hours cooling period without adverse events, and was lower than the controls (34.35°C [34-34.8°C]; p < 0.0001). Compared with historical controls, the cooled patients tended to have lower hospital mortality (75% vs 53.4%; p = 0.26), more ventilator-free days (9 [0-21.5] vs 0 [0-12]; p = 0.16), and higher day 3 P/F (255 [160-270] vs 171 [120-214]; p = 0.024). CONCLUSIONS: Neuromuscular blockade alone does not cause hypothermia but allowed acute respiratory distress syndrome patients to be effectively cooled. Results support conducting a randomized clinical trial of hypothermia in acute respiratory distress syndrome and the feasibility of studying acute respiratory distress syndrome patients receiving neuromuscular blockade.
OBJECTIVES: Prior studies suggest hypothermia may be beneficial in acute respiratory distress syndrome, but cooling causes shivering and increases metabolism. The objective of this study was to assess the feasibility of performing a randomized clinical trial of hypothermia in patients with acute respiratory distress syndrome receiving treatment with neuromuscular blockade because they cannot shiver. DESIGN: Retrospective study and pilot, prospective, open-label, feasibility study. SETTING: Medical ICU. PATIENTS: Retrospective review of 58 patients with acute respiratory distress syndrome based on Berlin criteria and PaO2/FIO2 less than 150 who received neuromuscular blockade. Prospective hypothermia treatment in eight acute respiratory distress syndromepatients with PaO2/FIO2 less than 150 receiving neuromuscular blockade. INTERVENTION: Cooling to 34-36°C for 48 hours. MEASUREMENTS AND MAIN RESULTS: Core temperature, hemodynamics, serum glucose and electrolytes, and P/F were sequentially measured, and medians (interquartile ranges) presented, 28-day ventilator-free days, and hospital mortality were calculated in historical controls and eight cooled patients. Average patient core temperature was 36.7°C (36-37.3°C), and fever occurred during neuromuscular blockade in 30 of 58 retrospective patients. In the prospectively cooled patients, core temperature reached target range less than or equal to 4 hours of initiating cooling, remained less than 36°C for 92% of the 48 hours cooling period without adverse events, and was lower than the controls (34.35°C [34-34.8°C]; p < 0.0001). Compared with historical controls, the cooled patients tended to have lower hospital mortality (75% vs 53.4%; p = 0.26), more ventilator-free days (9 [0-21.5] vs 0 [0-12]; p = 0.16), and higher day 3 P/F (255 [160-270] vs 171 [120-214]; p = 0.024). CONCLUSIONS:Neuromuscular blockade alone does not cause hypothermia but allowed acute respiratory distress syndromepatients to be effectively cooled. Results support conducting a randomized clinical trial of hypothermia in acute respiratory distress syndrome and the feasibility of studying acute respiratory distress syndromepatients receiving neuromuscular blockade.
Authors: Oscar J Bienvenu; Elizabeth Colantuoni; Pedro A Mendez-Tellez; Victor D Dinglas; Carl Shanholtz; Nadia Husain; Cheryl R Dennison; Margaret S Herridge; Peter J Pronovost; Dale M Needham Journal: Am J Respir Crit Care Med Date: 2011-12-08 Impact factor: 21.405
Authors: O J Bienvenu; J Gellar; B M Althouse; E Colantuoni; T Sricharoenchai; P A Mendez-Tellez; C Shanholtz; C R Dennison; P J Pronovost; D M Needham Journal: Psychol Med Date: 2013-02-26 Impact factor: 7.723
Authors: You Hwan Jo; Kyuseok Kim; Joong Eui Rhee; Gil Joon Suh; Woon Yong Kwon; Sang Hoon Na; Hasan B Alam Journal: Resuscitation Date: 2011-01-14 Impact factor: 5.262
Authors: Laurent Papazian; Jean-Marie Forel; Arnaud Gacouin; Christine Penot-Ragon; Gilles Perrin; Anderson Loundou; Samir Jaber; Jean-Michel Arnal; Didier Perez; Jean-Marie Seghboyan; Jean-Michel Constantin; Pierre Courant; Jean-Yves Lefrant; Claude Guérin; Gwenaël Prat; Sophie Morange; Antoine Roch Journal: N Engl J Med Date: 2010-09-16 Impact factor: 91.245
Authors: Guangxi Li; Michael Malinchoc; Rodrigo Cartin-Ceba; Chakradhar V Venkata; Daryl J Kor; Steve G Peters; Rolf D Hubmayr; Ognjen Gajic Journal: Am J Respir Crit Care Med Date: 2010-08-06 Impact factor: 21.405
Authors: Margaret S Herridge; Angela M Cheung; Catherine M Tansey; Andrea Matte-Martyn; Natalia Diaz-Granados; Fatma Al-Saidi; Andrew B Cooper; Cameron B Guest; C David Mazer; Sangeeta Mehta; Thomas E Stewart; Aiala Barr; Deborah Cook; Arthur S Slutsky Journal: N Engl J Med Date: 2003-02-20 Impact factor: 91.245
Authors: Gordon D Rubenfeld; Ellen Caldwell; Eve Peabody; Jim Weaver; Diane P Martin; Margaret Neff; Eric J Stern; Leonard D Hudson Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Niall D Ferguson; Eddy Fan; Luigi Camporota; Massimo Antonelli; Antonio Anzueto; Richard Beale; Laurent Brochard; Roy Brower; Andrés Esteban; Luciano Gattinoni; Andrew Rhodes; Arthur S Slutsky; Jean-Louis Vincent; Gordon D Rubenfeld; B Taylor Thompson; V Marco Ranieri Journal: Intensive Care Med Date: 2012-08-25 Impact factor: 17.440
Authors: David B Tulman; Stanislaw P A Stawicki; Bryan A Whitson; Saarik C Gupta; Ravi S Tripathi; Michael S Firstenberg; Don Hayes; Xuzhong Xu; Thomas J Papadimos Journal: BMC Anesthesiol Date: 2014-08-06 Impact factor: 2.217
Authors: Daniel Deredge; Patrick L Wintrode; Mohan E Tulapurkar; Ashish Nagarsekar; Yinghua Zhang; David J Weber; Paul Shapiro; Jeffrey D Hasday Journal: J Biol Chem Date: 2019-06-18 Impact factor: 5.157
Authors: C Autilio; M Echaide; A Cruz; C García-Mouton; A Hidalgo; E Da Silva; D De Luca; Jorid B Sørli; J Pérez-Gil Journal: Sci Rep Date: 2021-01-12 Impact factor: 4.379
Authors: Emily M Evans; Rebecca J Doctor; Brian F Gage; Richard S Hotchkiss; Brian M Fuller; Anne M Drewry Journal: Shock Date: 2019-08 Impact factor: 3.454